Emerald Advisers LLC purchased a new stake in shares of CeriBell (NASDAQ:CBLL - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 120,805 shares of the company's stock, valued at approximately $3,126,000. Emerald Advisers LLC owned approximately 0.34% of CeriBell at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. purchased a new stake in shares of CeriBell during the fourth quarter worth about $47,000. Rhumbline Advisers purchased a new position in CeriBell in the fourth quarter valued at about $320,000. Bank of New York Mellon Corp acquired a new stake in CeriBell during the 4th quarter valued at approximately $628,000. Charles Schwab Investment Management Inc. purchased a new stake in CeriBell during the 4th quarter worth approximately $2,500,000. Finally, Vanguard Group Inc. acquired a new position in shares of CeriBell in the 4th quarter valued at approximately $18,015,000.
Analysts Set New Price Targets
A number of analysts recently issued reports on CBLL shares. Canaccord Genuity Group restated a "buy" rating and issued a $33.00 price target on shares of CeriBell in a research note on Wednesday, February 26th. TD Cowen boosted their target price on shares of CeriBell from $31.00 to $36.00 and gave the stock a "buy" rating in a research report on Monday, December 9th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $32.60.
Check Out Our Latest Analysis on CeriBell
CeriBell Price Performance
CBLL traded down $0.37 during trading hours on Friday, hitting $19.46. 136,057 shares of the stock were exchanged, compared to its average volume of 243,690. The stock has a 50-day simple moving average of $22.33. CeriBell has a 12 month low of $18.69 and a 12 month high of $32.75.
CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The firm had revenue of $18.53 million for the quarter, compared to the consensus estimate of $17.55 million. As a group, research analysts anticipate that CeriBell will post -2.46 earnings per share for the current fiscal year.
CeriBell Company Profile
(
Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Further Reading
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
